

## Eucure Biopharma starts Phase I trial of YH002 (Anti-OX40 mAb)

14 March 2022 | News

Biocytogen Subsidiary, Eucure Biopharma, announces the first patient dosing for a Phase I multi-regional clinical trial of YH002 (Anti-OX40 mAb) in combination with YH001 (Anti-CTLA-4 mAb) in Australia



Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I multi-regional clinical trial (MRCT) of YH002 (anti-OX40 monoclonal antibody, mAb) in combination with YH001 (anti-CTLA-4 mAb) (No. YH002004) in Australia. This phase I MRCT will be conducted in Australia and China.

The clinical trial is an open-label, dose-escalation phase I study designed to evaluate the safety, tolerability and preliminary efficacy of YH002 in combination with YH001 in patients with advanced solid tumors. Pharmacokinetics and immunogenicity of YH001 and YH002 will also be evaluated.

Eucure Biopharma has previously completed mono-dose-escalation studies for YH001 and YH002. The results show that both YH001 and YH002 have good tolerance and safety.

Dr. Yuelei Shen, Chairman and CEO of Biocytogen and Eucure Biopharma, said, "Both YH001 and YH002 are developed from Biocytogen's evidence-based *in vivo* efficacy screening platform. Using animal models, we found for the first time, that combination of YH002 and YH001 has very good antitumor activity. We expect the results from animal models can be verified in patients. We are hopeful that these platforms will continue to drive the discovery and development of novel therapeutic antibodies, ADCs and bispecific ADCs for future clinical benefit."